全文获取类型
收费全文 | 148391篇 |
免费 | 11372篇 |
国内免费 | 4193篇 |
专业分类
耳鼻咽喉 | 1030篇 |
儿科学 | 3776篇 |
妇产科学 | 2495篇 |
基础医学 | 8401篇 |
口腔科学 | 2957篇 |
临床医学 | 18665篇 |
内科学 | 25989篇 |
皮肤病学 | 2400篇 |
神经病学 | 7042篇 |
特种医学 | 4331篇 |
外国民族医学 | 40篇 |
外科学 | 13870篇 |
综合类 | 21194篇 |
现状与发展 | 27篇 |
一般理论 | 4篇 |
预防医学 | 7136篇 |
眼科学 | 2122篇 |
药学 | 12628篇 |
95篇 | |
中国医学 | 11942篇 |
肿瘤学 | 17812篇 |
出版年
2024年 | 397篇 |
2023年 | 2758篇 |
2022年 | 4819篇 |
2021年 | 6495篇 |
2020年 | 6054篇 |
2019年 | 5466篇 |
2018年 | 5221篇 |
2017年 | 5665篇 |
2016年 | 5942篇 |
2015年 | 5698篇 |
2014年 | 10245篇 |
2013年 | 13194篇 |
2012年 | 8523篇 |
2011年 | 9098篇 |
2010年 | 7483篇 |
2009年 | 6943篇 |
2008年 | 6873篇 |
2007年 | 7277篇 |
2006年 | 6430篇 |
2005年 | 5736篇 |
2004年 | 4774篇 |
2003年 | 4313篇 |
2002年 | 3474篇 |
2001年 | 3112篇 |
2000年 | 2623篇 |
1999年 | 2065篇 |
1998年 | 1723篇 |
1997年 | 1492篇 |
1996年 | 1221篇 |
1995年 | 1090篇 |
1994年 | 902篇 |
1993年 | 715篇 |
1992年 | 642篇 |
1991年 | 587篇 |
1990年 | 478篇 |
1989年 | 447篇 |
1988年 | 435篇 |
1987年 | 395篇 |
1986年 | 323篇 |
1985年 | 396篇 |
1984年 | 355篇 |
1983年 | 242篇 |
1982年 | 284篇 |
1981年 | 269篇 |
1980年 | 252篇 |
1979年 | 226篇 |
1978年 | 146篇 |
1977年 | 117篇 |
1976年 | 114篇 |
1973年 | 72篇 |
排序方式: 共有10000条查询结果,搜索用时 2 毫秒
31.
38例非小细胞癌脑转移的综合治疗分析 总被引:1,自引:1,他引:0
目的探讨非小细胞肺癌脑转移的有效治疗方案.方法对38例非小细胞肺癌脑转移患者进行头部、胸部放疗并结合全身化疗的综合治疗.结果近期疗效的有效率为76.3%(29/38).神经精神症状缓解率73.7%(28/38),肺部症状缓解率60.5%(23/38).1年生存率31.5%(12/38),2 a生存率10.5%(4/38).结论合理采用综合治疗可有效提高非小细胞肺癌脑转移患者的生存率. 相似文献
32.
[目的]观察比较异环磷酰胺(IFO)、顺铂(DDP)、5-氟尿嘧啶(5-Fu)联合方案(IPF方案)与DDP,5-Fu(PF方案)治疗晚期复发鼻咽癌(Ⅲ-Ⅳ期)的近期疗效及毒副反应。[方法]136例均经病理证实为晚期复发鼻咽癌患者,随机分为IPF组69例,PF组67例(对照组)[结果]IPF组和PF组有效率分别为69.56%(48/69)和43.3%(29/67),两组间差异有显著性(X2=8.519,P<0.01)。中位生存期:IPF组16个月(8-34个月),PF组为6.5个月(4-21个月),两组间差异有显著性(X2=22.36,P<0.05)。毒副作用主要为骨髓抑制,Ⅲ-Ⅳ度白细胞下降率IPF组为49.4%,PF组为5.97%,两组差异有显著性(X2=29.54,P<0.01)。Ⅲ-Ⅳ度血小板下降率IPF组为29.18%,PF组为0%(X2=30.29,P<0.01);Ⅲ-Ⅳ度消化道反应两组的发生率分别为15.94%和11.94%(x2=0.234,P>0.01).且以Ⅲ度为主。[结论]以IFO为主的方案联合治疗晚期复发鼻咽癌疗效好,毒副反应能耐受,可作为一线方案。 相似文献
33.
目的观察奥兰扎平治疗精神分裂症的临床疗效与安全性.方法选择58例精神分裂症病人,开始给予奥兰扎平5mg*d-1,3d后根据临床疗效、副反应情况酌情增加剂量,最大剂量不超过20mg*d-1,治疗8周.治疗前及治疗后每2周用PANSS、CGI、TESS量表评定1次.结果治疗后PANSS总分、各因子分较治疗前显著下降(P<0.01),副反应主要有抗胆碱症状、过度镇静、体重增加、一过性丙氨酸氨基转移酶升高.结论奥兰扎平是一种安全、有效、副作用较轻的抗精神病药. 相似文献
34.
Iver A. Langmoen Tryggve Lundar Ingebjørg Storm-Mathisen Sverre O. Lie Karl H. Hovind 《Child's nervous system》1991,7(1):13-15
We present 36 consecutive patients with intrinsic glioma of the pons. Tumors with exophytic expansion were excluded. There were 16 females and 20 males, ranging in age from 2 to 13 years, median 6 years. The most common presenting symptoms were cranial nerve dysfunction. unsteadiness of gait, and hemiparesis. Computed tomography (CT) showed a hypodense (17/21) or isodense (4/21) expansion of the pons. Five tumors had areas of contrast enhancement. Following information about prognosis and possible types of management, parents decided for or against radiation therapy: twentyfour children underwent irradiation and 12 did not. Median survival among children receiving a full course of irradiation was 280 days, compared to 140 days in an equivalent group of non-irradiated children. Hemiparesis presenting without cranial nerve symptoms and contrast enhancement on CT scan were poor prognostic factors, whereas sex, age, and duration of symptoms at diagnosis were unrelated to prognosis. 相似文献
35.
Galanin-like immunoreactivity has been visualized in nerve fibers in the islets of Langerhans, suggesting an involvement of
galanin in the neural regulation of islet function. In this study, we investigated the effects of galanin on basal and stimulated
insulin and glucagon secretion by infusing the peptide at three different dose rates in rats. We also studied the direct effect
of galanin on insulin secretion from freshly isolated rat islets. At 320 pmol/kg/min, but not at 20 or 80 pmol/kg/min, galanin
lowered basal plasma insulin levels. In contrast, basal plasma glucagon levels were lowered by galanin already at 20 and 80
pmol/kg/min. Furthermore, galanin inhibited both glucose- and arginine-induced insulin release at all three dose levels, whereas
arginine-induced glucagon release was not affected by galanin. Glucose-stimulated insulin secretion from isolated rat islets
was dose-dependently suppressed by galanin (10-6-10-8M). Therefore, it is concluded that galanin in rats inhibits insulin secretion, both in vivo and in vitro, and that at lower
dose levels, the peptide also inhibits basal glucagon release. 相似文献
36.
TRH、EGF及地塞米松促进未成熟胎肺组织分化及表面活性物质合成的研究 总被引:5,自引:3,他引:2
目的 比较TRH、EGF与地塞米松对未成熟胎肺形态发育及表面活性物质水平的影响。方法 在兔妊娠第22-24d或第24-26d分别用TRH、EGF或地塞米松母体静脉注射治病,通过光镜、图像分析及电镜等技术观察胎肺的形态结构,并检测胎肺的磷脂水平。结果 光镜下,TRH、EGF与地塞米松治疗组第25d及27d胎肺肺泡腔、肺泡间隔发育均明显好于对照组;EGF、TRH与地塞米松治疗组第27d胎肺的肺泡腔与肺泡间隔的面积比无明显差异。但EGF和TRH治疗组第25d胎肺的肺泡腔与肺泡间隔之比明显小于地塞米松治疗组。电镜下,三个治疗组第27d胎肺内含有板层体的Ⅱ型上皮细胞数量明显多于对照组,但各治疗组及对照组第25d的胎肺Ⅱ型上皮细胞胞浆内几乎未见明显板层体,相反胞浆内糖原含量却非常丰富。此外,三个治疗组27d胎肺的磷脂水平均明显高于对照组。结论 EGF、TRH及地塞米松在兔妊娠第24-26d母体治疗均能促进胎肺的形态发育和表面活性物质的合成,三种治疗方法对胎肺的影响程序无明显不同;在妊娠第22-24d治疗,地塞米松对胎肺形态结构的促进作用较EGF和TRH更明显,但三者对Ⅱ型上皮细胞分化及表面活性物质的合成均无明显影响。 相似文献
37.
YS Nagar S Singh V Sawlani L Pal K Dimri P Lal 《Journal of Medical Imaging and Radiation Oncology》2005,49(2):160-162
A rare case of an advanced primary broad ligament carcinoma is discussed, with a review of the literature regarding its incidence, presentation and management. This patient showed a complete response to adjuvant cisplatin-based chemotherapy following panhysterectomy and is presently without any evidence of disease, 15 months after completion of her treatment. 相似文献
38.
Rodica Pop-Busui Jiang Lu Neuza Lopes Teresa L. Z. Jones and the BARI D Investigators 《Journal of the peripheral nervous system : JPNS》2009,14(1):1-13
Abstract We evaluated the associations between glycemic therapies and prevalence of diabetic peripheral neuropathy (DPN) at baseline among participants in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial on medical and revascularization therapies for coronary artery disease (CAD) and on insulin-sensitizing vs. insulin-providing treatments for diabetes. A total of 2,368 patients with type 2 diabetes and CAD was evaluated. DPN was defined as clinical examination score >2 using the Michigan Neuropathy Screening Instrument (MNSI). DPN odds ratios across different groups of glycemic therapy were evaluated by multiple logistic regression adjusted for multiple covariates including age, sex, hemoglobin A1c (HbA1c), and diabetes duration. Fifty-one percent of BARI 2D subjects with valid baseline characteristics and MNSI scores had DPN. After adjusting for all variables, use of insulin was significantly associated with DPN (OR = 1.57, 95% CI: 1.15–2.13). Patients on sulfonylurea (SU) or combination of SU/metformin (Met)/thiazolidinediones (TZD) had marginally higher rates of DPN than the Met/TZD group. This cross-sectional study in a cohort of patients with type 2 diabetes and CAD showed association of insulin use with higher DPN prevalence, independent of disease duration, glycemic control, and other characteristics. The causality between a glycemic control strategy and DPN cannot be evaluated in this cross-sectional study, but continued assessment of DPN and randomized therapies in BARI 2D trial may provide further explanations on the development of DPN. 相似文献
39.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab). 相似文献
40.
R. A. Bradbury D. Shirkhedkar A. R. Glanville L. V. Campbell 《Internal medicine journal》2009,39(6):384-388
Background: The aim of this study was to determine whether pre-existing diabetes mellitus increases the risk of rejection, infection and/or death in cystic fibrosis patients undergoing bilateral sequential single-lung transplantation.
Methods: A retrospective audit of 25 consecutive patients with cystic fibrosis who underwent bilateral sequential single-lung transplantation between 1 January 2003 and 31 December 2005 at a tertiary referral hospital was carried out.
Results: Although 32% patients had diabetes diagnosed before lung transplantation, 92% had random blood glucose levels ≥11.1 mmol/L requiring insulin during admission. Patients with pre-existing diabetes had increased infection-related (3.9 vs 1.2, P = 0.01) and putative rejection-related (1.4 vs 0.5, P = 0.04) hospital admissions post-transplantation compared with those without diabetes pre-transplant. During the period of observation, four of eight patients with a prior diagnosis of diabetes died compared with none of 17 patients without prior diabetes ( P = 0.0055).
Conclusion: Almost all cystic fibrosis patients develop hyperglycaemia after lung transplantation, but patients with prior diabetes have more complication-related admissions to hospital and a higher mortality rate. 相似文献
Methods: A retrospective audit of 25 consecutive patients with cystic fibrosis who underwent bilateral sequential single-lung transplantation between 1 January 2003 and 31 December 2005 at a tertiary referral hospital was carried out.
Results: Although 32% patients had diabetes diagnosed before lung transplantation, 92% had random blood glucose levels ≥11.1 mmol/L requiring insulin during admission. Patients with pre-existing diabetes had increased infection-related (3.9 vs 1.2, P = 0.01) and putative rejection-related (1.4 vs 0.5, P = 0.04) hospital admissions post-transplantation compared with those without diabetes pre-transplant. During the period of observation, four of eight patients with a prior diagnosis of diabetes died compared with none of 17 patients without prior diabetes ( P = 0.0055).
Conclusion: Almost all cystic fibrosis patients develop hyperglycaemia after lung transplantation, but patients with prior diabetes have more complication-related admissions to hospital and a higher mortality rate. 相似文献